Climb Bio, Inc. CLYM
12.25 USD +0.51 (+4.34%)
At closeNov 11, 2026, 4:00 PM EST
12.25 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
11.49 Day range 12.44
1.64 52-week range 18.33
- YTD
- +206.25%
- 1 year
- +544.74%
News
benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.
benzinga.com Climb Bio Q3 EPS $(0.18) Beats $(0.20) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 5.26 percent increase over losses of $(0.19) per…
globenewswire.com Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in…- benzinga.com Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
globenewswire.com Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
globenewswire.com Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
benzinga.com Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…
globenewswire.com Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…- benzinga.com Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval~70% reduction in Gd-IgA1 at 12 weeks~33-day half-lifeNAVIGATE-2 Phase 2 trial enrolling, with initial data…
globenewswire.com Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data…
benzinga.com Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28 Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
zacks.com Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year? Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
seekingalpha.com Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash,…
benzinga.com Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026 Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
globenewswire.com Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
benzinga.com Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25 Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.
benzinga.com Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
- benzinga.com B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30 B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
benzinga.com BTIG Maintains Buy on Climb Bio, Raises Price Target to $32 BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
marketbeat.com Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing…
benzinga.com Baird Maintains Outperform on Climb Bio, Raises Price Target to $25 Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
benzinga.com Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney…
benzinga.com Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.
globenewswire.com Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse…
globenewswire.com Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $24.
- benzinga.com Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25 Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.
- benzinga.com Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 38.46 percent decrease over losses of $(0.13)…
defenseworld.net Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the…
defenseworld.net Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush…
benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $17 to $20.
seekingalpha.com Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility- benzinga.com HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.
- benzinga.com Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies Up to $100,000,000Common StockWe have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated as of June 12, 2026, relating to the sale of shares…
benzinga.com Why Is Climb Bio Stock Gaining Friday? Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder…
benzinga.com Why Is Climb Bio Stock Gaining Friday? Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletion and strong platelet responses.- benzinga.com BTIG Maintains Buy on Climb Bio, Raises Price Target to $20 BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $19 to $20.
- benzinga.com Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune Thrombocytopenia Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b…
globenewswire.com Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment…
benzinga.com Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…- benzinga.com Guggenheim Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $35 Guggenheim analyst Yatin Suneja initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $35.
- benzinga.com Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD) data, as well as updated safety data from the ongoing Phase 1 studies of CLYM116 in healthy…
- benzinga.com Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026 Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summerInitiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in…
globenewswire.com Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
globenewswire.com Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
marketbeat.com Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two…
benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.- benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.
- benzinga.com Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.48 percent increase over losses of $(0.31)…